Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094126 | 1.00 | KMT2A (0.39) | KMT2AGAAPSEN1PSEN2APH1B | |
| SCHEMBL16119912 | 1.00 | KMT2A (0.39) | KMT2AGAAPSEN1PSEN2APH1B | |
| SCHEMBL29028756 | 0.90 | EPAS1 (0.40) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20573470 | 0.85 | BCHE (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18895510 | 0.85 | BCHE (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7637176 | 0.83 | GAA (0.45) | KMT2AGAABCHEACHEAGER | |
| SCHEMBL29028609 | 0.81 | PSEN1 (0.40) | KMT2AGAAPSEN1PSEN2APH1B | |
| SCHEMBL11988007 | 0.79 | VDR (0.45) | GAAVDRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL491994 | 0.79 | VDR (0.45) | GAAVDRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28646777 | 0.78 | HTT (0.44) | KMT2AGAABCHEACHEAGER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253548-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10899732-B2 | Substituted benzamides useful as sodium channel blockers | GENENTECH, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| CN-105793238-B | Substituted benzamides and methods of use thereof | 基因泰克公司 | 2019-12-24 | — | — | CN | disclosed |
| US-10179767-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180346441-A1 | SUBSTITUTED BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS | GENENTECH, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3380466-A1 | SUBSTITUTED BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS | Genentech, Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-3297989-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2017091592-A1 | SUBSTITUTED BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS | GENENTECH, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| WO-2016191312-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160340309-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| EP-2968280-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2014153037-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179767-B2 | Substituted benzamides and methods of use thereof | SCN7A, SCN2B, SCN5A | KMT2A 1284/4885GAA 831/4885PSEN1 1531/4885 |
| US-20160340309-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | SCN7A, SCN2B, SCN5A | KMT2A 1284/4885GAA 831/4885PSEN1 1531/4885 |
| US-20180346441-A1 | SUBSTITUTED BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS | SCN2B, SCN1B, CACNA1E | KMT2A 587/4885GAA 2314/4885PSEN1 3933/4885 |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | P2RX3, P2RX1, P2RX4 | KMT2A 3498/4885GAA 3264/4885PSEN1 3334/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | KMT2A 277/4885GAA 1686/4885PSEN1 2645/4885 |
| US-10899732-B2 | Substituted benzamides useful as sodium channel blockers | SCN2B, SCN1B, CACNA1E | KMT2A 587/4885GAA 2314/4885PSEN1 3933/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | KMT2A 251/4885GAA 1650/4885PSEN1 2110/4885 |
| US-20210253548-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | RDX, RRM1, BRIX1 | KMT2A 163/4885GAA 1201/4885PSEN1 4331/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | KMT2A 323/4885GAA 2199/4885PSEN1 1689/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | KMT2A 277/4885GAA 1686/4885PSEN1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.